farletuzumab farletuzumab farletuzumab (morab-003) is a humanized monoclonal antibody of igg1/κ which is being investigated for the treatment of ovarian cancer. farletuzumabmonoclonal antibodytypewhole antibodysourcehumanizedtargetfr-alphaclinical dataroutes ofadministrationintravenous injectionatc codenoneidentifierscas number896723-44-7 nchemspidernoneunii2o09bg0owakeggd09343 ychemical and physical dataformulac6466h9928n1716o2020s42molar mass145371.06 g·mol−1 ny (what is this?) (verify) this drug was developed by morphotek, inc. it is targeted at folate receptor alpha (frα) which is overexpressed in some cancers such as epithelial ovarian cancer (eoc) and non-small-cell lung carcinoma. mechanism of action farletuzumab uses the following mechanisms of action: antibody-dependent cellular cytotoxicity complement-dependent cytotoxicity inhibition of interaction between frα and lyn kinase induces cell death associated with autophagy adverse effects common adverse effects include hypersensitivity reactions, fever, chills, headache, fatigue, and diarrhea.